Founded in South San Francisco, Standard BioTools Inc., previously known as Fluidigm Corp., is dedicated to accelerating life sciences research through essential, standardized technologies. The company focuses on providing tools that enable researchers to scale and speed up their investigations into cell function, cancer-immune cell interactions, and biomarker discovery. Their products and services are designed to deliver consistent, reliable, and repeatable results, thereby promoting the development of breakthrough medicines more efficiently.
Standard BioTools has garnered attention for its innovative contributions to the life sciences field. The company has established a robust portfolio of technologies that are widely used in research institutions and pharmaceutical companies. Notable investors and affiliated individuals have supported its mission to enhance scientific discovery. Through its impactful technologies, Standard BioTools has significantly advanced the pace and quality of biomedical research, contributing to the development of new therapeutic solutions.
